Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Patients being prescribed weight-loss drugs should be required to see a dietitian, the nutrition industry says as ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

The multinational claims Mylan Pharmaceuticals’ generic of its blockbuster weight loss drug infringes another new patent | Complaint similar but separate to previous lawsuit against Mylan and Sun ...

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.